Your browser doesn't support javascript.
loading
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.
Siva, Shankar; Bressel, Mathias; Mai, Tao; Le, Hien; Vinod, Shalini; de Silva, Harini; Macdonald, Sean; Skala, Marketa; Hardcastle, Nicholas; Rezo, Angela; Pryor, David; Gill, Suki; Higgs, Braden; Wagenfuehr, Kassandra; Montgomery, Rebecca; Awad, Raef; Chesson, Brent; Eade, Thomas; Wong, Wenchang; Sasso, Giuseppe; De Abreu Lourenco, Richard; Kron, Tomas; Ball, David; Neeson, Paul.
Afiliação
  • Siva S; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Victoria, Australia.
  • Bressel M; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.
  • Mai T; Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Victoria, Australia.
  • Le H; Radiation Oncology Centre, Princess Alexandra Hospital, Queensland, Australia.
  • Vinod S; Department of Radiation Oncology, Royal Adelaide Hospital, South Australia, Australia.
  • de Silva H; Cancer Therapy Centre, Liverpool Hospital, New South Wales, Australia.
  • Macdonald S; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Skala M; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Hardcastle N; Royal Hobart Hospital, Tasmania, Australia.
  • Rezo A; Department of Physical Sciences, Peter MacCallum Cancer Centre, Victoria, Australia.
  • Pryor D; Canberra Hospital, Garran, Australian Capital Territory, Australia.
  • Gill S; Radiation Oncology Centre, Princess Alexandra Hospital, Queensland, Australia.
  • Higgs B; Sir Charles Gairdner Hospital, Western Australia, Australia.
  • Wagenfuehr K; Department of Radiation Oncology, Royal Adelaide Hospital, South Australia, Australia.
  • Montgomery R; Trans Tasman Radiation Oncology Group (TROG) Cancer Research, New South Wales, Australia.
  • Awad R; Trans Tasman Radiation Oncology Group (TROG) Cancer Research, New South Wales, Australia.
  • Chesson B; Royal Hobart Hospital, Tasmania, Australia.
  • Eade T; Department of Radiation Therapy, Peter MacCallum Cancer Centre, Victoria, Australia.
  • Wong W; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Sasso G; Department of Radiation Oncology, Prince of Wales Hospital, New South Wales, Australia.
  • De Abreu Lourenco R; Radiation Oncology Department, Auckland City Hospital, New Zealand.
  • Kron T; Centre for Health Economics Research and Evaluation, University of Technology Sydney, New South Wales, Australia.
  • Ball D; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.
  • Neeson P; Radiation Oncology Centre, Princess Alexandra Hospital, Queensland, Australia.
JAMA Oncol ; 7(10): 1476-1485, 2021 Oct 01.
Article em En | MEDLINE | ID: mdl-34455431
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radiocirurgia / Neoplasias Tipo de estudo: Clinical_trials / Etiology_studies Limite: Child / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radiocirurgia / Neoplasias Tipo de estudo: Clinical_trials / Etiology_studies Limite: Child / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article